Hello. I tried to reconcile things but its hard to follow without full account. What I noticed was:
1. Only $609,000 in cash receipts, thus, as reported, more cash from the $3.4 to $4.1M AstraZeneca deal is due in the near future. Note: at 30/6/24, there was $557,000 in receivables outstanding, therefore the $609,000 may not even be all AstraZenenca cash. However, it is also clear not all of the $3.4 to $4.1M AstraZeneca deal is due in the near term.
2. $551,000 cash outflow for operating costs & manufacturing costs for the quarter. Note: for last year this entire annual amount was $1,180,000, which resulted in $1,618,000 in inventory at 30/6/24. Report says a $900,000 spend to replenish inventory for the next quarter. Ignoring this inventory spend, it appears the quarterly spend for other expenses is around $1,500,000 for the quarter.
3. LBT claims they will be cashflow positive for the next two quarters.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)